Alnylam is teaming up with Medtronic to deliver its huntingtinin RNAi therapy using Medtronic’s implantable delivery system. The virtual non-profit biotech, CHDI, is funding the study. This collaboration represents a trend in CNS disease therapeutics towards drug-device combinations to overcome the particular challenge of drug delivery across the blood brain barrier. Along related lines, Swedish company NeuroNova is currently conducting a Phase I/II clinical trial that employs Medtronic’s pumps to deliver its ALS drug directly into the CNS.
Click here to read more.Share this: